KK-2260

N/A

Report date: 2024/11/28 10:10:54

Base Information

Drug NameKK-2260
Drug Alias NameKK2260KK-2260
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionTransferrin receptor protein 1 antagonistsEpidermal growth factor receptor erbB1 antagonists
TargetsTransferrin receptor protein 1Epidermal growth factor receptor erbB1
Therapy Area/IndicationsSolid tumoursEsophageal NeoplasmsSquamous Cell Carcinoma of Head and Neck
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesKyowa Kirin Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesKyowa Kirin Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursEsophageal NeoplasmsSquamous Cell Carcinoma of Head and Neck
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A